Actively Recruiting
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Led by AstraZeneca · Updated on 2026-04-22
400
Participants Needed
76
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
CONDITIONS
Official Title
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide informed consent before any study procedures
- Be between 12 and 80 years old at the time of enrollment
- Have a documented history of physician-diagnosed asthma
- Show documented lung function reversibility or variability indicating asthma
- Be on stable medium to high dose inhaled corticosteroids plus long-acting beta-agonist treatment
- May also be on stable leukotriene receptor antagonists, long-acting muscarinic antagonists, or theophylline
- Have an asthma control questionnaire score (ACQ-5) of 1.5 or higher at enrollment
- Have had at least one asthma exacerbation requiring systemic corticosteroids or hospitalization in the past year
- Weigh at least 40 kg
- Female participants of childbearing potential must use highly effective contraception and have a negative pregnancy test at enrollment
You will not qualify if you...
- Unable or unwilling to follow study visit schedule or reduce asthma therapy as directed
- Have other significant lung diseases besides asthma, including infections or diseases causing high eosinophil counts
- Current smokers or former smokers with 10 or more pack-years (must have quit at least 6 months if less than 10 pack-years)
- History of alcohol or drug abuse in the past year
- Untreated or unresponsive helminth parasitic infection within 24 weeks prior to enrollment
- History of severe allergic reaction to biological therapies or components of the study drug
- Recent respiratory infections or exacerbations requiring systemic steroids or antibiotics within 30 days prior to enrollment
- Known immunodeficiency, including HIV
- History of cancer within 5 years, except certain treated skin or cervical cancers
- Prior allogeneic bone marrow transplant or recent whole blood transfusion
- Unstable major medical conditions that might affect safety or study results
- Use of oral corticosteroids in the 4 weeks before enrollment
- Use of immunosuppressive or investigational therapies within specified washout periods
- Receipt of live vaccines within 30 days before first dose of study drug
- Use of prohibited medications or failure to complete required washout
- Recent bronchial thermoplasty or use of anti-asthmatic traditional Chinese medicines within specified timeframes
- Participation in other investigational studies
- Significant abnormal physical or lab findings that pose risk or confound results
- Pregnant, breastfeeding, or lactating females
- Involvement in the study planning or conduct
- Prior enrollment in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 76 locations
1
Research Site
Beijing, China, 100020
Not Yet Recruiting
2
Research Site
Beijing, China, 100191
Actively Recruiting
3
Research Site
Beijing, China, 100730
Actively Recruiting
4
Research Site
Beijing, China, 100730
Not Yet Recruiting
5
Research Site
Beijing, China, 102300
Not Yet Recruiting
6
Research Site
Beijing, China, 10730
Not Yet Recruiting
7
Research Site
Beijing, China, 211405
Not Yet Recruiting
8
Research Site
Binzhou, China, 256606
Not Yet Recruiting
9
Research Site
Changsha, China, 410008
Not Yet Recruiting
10
Research Site
Changsha, China, 430033
Actively Recruiting
11
Research Site
Chengdu, China, 610041
Actively Recruiting
12
Research Site
Chengdu, China, 610072
Actively Recruiting
13
Research Site
Chengdu, China, 610095
Not Yet Recruiting
14
Research Site
Chengdu, China, 610500
Actively Recruiting
15
Research Site
Chongqing, China, 400042
Not Yet Recruiting
16
Research Site
Chongqing, China, 400072
Not Yet Recruiting
17
Research Site
Deyang, China, 618000
Not Yet Recruiting
18
Research Site
Fuzhou, China, 350001
Not Yet Recruiting
19
Research Site
Guangzhou, China, 510080
Not Yet Recruiting
20
Research Site
Guangzhou, China, 510100
Not Yet Recruiting
21
Research Site
Guangzhou, China, 510163
Not Yet Recruiting
22
Research Site
Guangzhou, China, 510180
Not Yet Recruiting
23
Research Site
Guangzhou, China, 510280
Actively Recruiting
24
Research Site
Guangzhou, China, 510515
Actively Recruiting
25
Research Site
Guangzhou, China, 510620
Actively Recruiting
26
Research Site
Guiyang, China, 510630
Not Yet Recruiting
27
Research Site
Hangzhou, China, 310003
Not Yet Recruiting
28
Research Site
Hangzhou, China, 310006
Not Yet Recruiting
29
Research Site
Hangzhou, China, 310016
Not Yet Recruiting
30
Research Site
Hefei, China, 230061
Not Yet Recruiting
31
Research Site
Hefei, China, 230601
Not Yet Recruiting
32
Research Site
Hohhot, China, 010017
Not Yet Recruiting
33
Research Site
Jiangmen, China, 529000
Not Yet Recruiting
34
Research Site
Jinan, China, 250012
Not Yet Recruiting
35
Research Site
Jinan, China, 250014
Not Yet Recruiting
36
Research Site
Jinan, China, 250021
Not Yet Recruiting
37
Research Site
Jining, China, 272006
Not Yet Recruiting
38
Research Site
Kunming, China, 650032
Not Yet Recruiting
39
Research Site
Leshan, China, 614000
Actively Recruiting
40
Research Site
Linyi, China, CN-276003
Not Yet Recruiting
41
Research Site
Luzhou, China, 646000
Not Yet Recruiting
42
Research Site
Meizhou, China, 514700
Not Yet Recruiting
43
Research Site
Mianyang, China, 621000
Actively Recruiting
44
Research Site
Nanchang, China, 330006
Actively Recruiting
45
Research Site
Nanjing, China, 210029
Not Yet Recruiting
46
Research Site
Nanjing, China, 211100
Not Yet Recruiting
47
Research Site
Nanning, China, 530000
Not Yet Recruiting
48
Research Site
Ningbo, China, 315010
Actively Recruiting
49
Research Site
Quanzhou, China, 362000
Not Yet Recruiting
50
Research Site
Shanghai, China, 200000
Not Yet Recruiting
51
Research Site
Shanghai, China, 200003
Not Yet Recruiting
52
Research Site
Shanghai, China, 200025
Not Yet Recruiting
53
Research Site
Shanghai, China, 200032
Not Yet Recruiting
54
Research Site
Shanghai, China, 200433
Not Yet Recruiting
55
Research Site
Shanghai, China, 310000
Actively Recruiting
56
Research Site
Shantou, China, 515041
Not Yet Recruiting
57
Research Site
Shenyang, China, 110001
Not Yet Recruiting
58
Research Site
Shenzhen, China, 518020
Not Yet Recruiting
59
Research Site
Shenzhen, China, 518036
Not Yet Recruiting
60
Research Site
Shijiazhuang, China, 054001
Actively Recruiting
61
Research Site
Suining Shi, China, 629000
Actively Recruiting
62
Research Site
Suzhou, China, 215006
Actively Recruiting
63
Research Site
Taiyuan, China, 030001
Not Yet Recruiting
64
Research Site
Taiyuan, China, 030032
Not Yet Recruiting
65
Research Site
Tianjin, China, 300192
Not Yet Recruiting
66
Research Site
Weifang, China, 261000
Not Yet Recruiting
67
Research Site
Wenzhou, China, 325027
Actively Recruiting
68
Research Site
Wuhan, China, 430030
Not Yet Recruiting
69
Research Site
Wuhan, China, 430060
Actively Recruiting
70
Research Site
Wuxi, China, 214023
Not Yet Recruiting
71
Research Site
Xi'an, China, 710061
Not Yet Recruiting
72
Research Site
Zhangzhou, China, 363099
Not Yet Recruiting
73
Research Site
Zhanjiang, China, 524004
Not Yet Recruiting
74
Research Site
Zhengzhou, China, 450003
Not Yet Recruiting
75
Research Site
Zhengzhou, China, 450007
Actively Recruiting
76
Research Site
Zhongshan, China, 528403
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here